Replies to post #2544 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Yes, it was KK that brought JT to Spectrum. From an Oct 2012 PR

”The addition of Mr. Turgeon following appointment of Mr. Keller earlier this year is part of a planned strategy for expedited growth of Spectrum Pharmaceuticals.[- Dr Raj]”

“Having worked with Joe for over twenty years at Amgen, it is my honor to warmly welcome Mr. Turgeon to Spectrum. His impressive sales record at Amgen will be a welcome addition as Spectrum continues expanding its commercial presence on the global market,” stated Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum Pharmaceuticals, Inc. “Joe’s leadership and strategic skills will be broadly beneficial to Spectrum as we pursue our aggressive international growth plans.”

Regarding some type of hook up, i'm just having fun throwing darts at the side of the barn but regarding synergy, they do have different mechanisms of action which one looks for in a combo trial. Having said that I don't think it's in Spectrum's interest. Preliminary DS-8201 data shows much less effectiveness in EGFR and comparable effectiveness in HER2. So why bother unless Daiichi gives an offer they can't refuse.

After I posted last night, I started thinking why isn't DS-8201 as effective in EGFR since the EGFR and HER2 ex20in "pockets are extremely very similar" (Dr H quote). How does DS-8201 attack it where it's more active in HER2? From the MDACC data we know that pozi doesn't have this problem. That bodes well for the basket study too.